Citations

Clear

186 citation(s) found for "Frantz, R".

Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis
Yogeswaran, Athiththan , Fünderich, Meike , Balasubramanian, Aparna , Konswa, Ziad , Kiely, David G. , Thenappan, Thenappan , Eichstaedt, Christina A. , Olschewski, Horst , Sweatt, Andrew J. , Zamanian, Roham T. , Giannakoulas, George , Elwing, Jean , Beckmann, Stephan, Olsson, Karen M. , Held, Matthias , Halank, Michael , Milger, Katrin , Pausch, Christine , Pittrow, David , Majeed, Raphael W. , Wilhelm, Jochen , Tello, Khodr , Seeger, Werner , Ghouleh, Imad Al , Sіrenko, Yu.M. , Balasubramanian, Aparna , Lawrie, Allan , Wilkins, Martin , Howard, Luke , Olschewski, Horst , Frantz, Robert, Stadler, Stefan , Hoeper, Marius M , Thenappan, Thenappan , Seeger, Werner , Yogeswaran, Athiththan , Kiely, David , Majeed, Raphael W , Hassoun, Paul M. , Saleh, Khaled, Grünig, Ekkehard , Wilkins, Martin R. , Kovács, Gábor , Cajigas, Héctor , Frantz, Robert P. , Sabbour, Hani Mohamed , Arvanitaki, Alexandra , Jose, Arun , Ewert, Ralf , Behr, Jürgen , Ghofrani, Hossein Ardeschir , Grimminger, Friedrich , Hoeper, Marius M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 7, 2025 | Volume: 211 | Issue: 10 | Pages: 1855-1866

10.1164/rccm.202412-2371oc | PMID 40772955 Get It

Abstract Rationale Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. Objectives The Pulmonary Vascular Research Institute GoDeep metaregistry collects real-world data of patients with PH from international PH referral centers. Methods Patients with ILD-PH and relevant subgroups (idiopathic interstitial pneumonia [IIP], idiopathic pulmonary fibrosis [IPF]) were stratified by pulmonary vascular resistance (PVR). Kaplan-Meier survival analyses and adjusted Cox proportional hazards models were employed, additionally accounting for immortal time bias, sensitivity analyses, Heller explained relative risk statistics, and target trial emulation framework analysis. Measurements and Main Results Among 34,482 patients, 940 with hemodynamically fully characterized incident ILD-PH (median age, 67 [IQR, 59–74] yr) were identified. A total of 62% had severe ILD-PH with PVR >5 Wood units (WU) and poor survival rates (29% and 18% at 3 and 5 yr), significantly worse than patients with ILD-PH with PVR ≤5 WU and patients with pulmonary arterial hypertension. Survival was poorest in severe IPF-PH. A total of 59% of all patients ILD-PH received PH-targeted therapy, predominantly phosphodiesterase-5 inhibitors (PDE5is). PDE5i treatment was consistently associated with significantly improved survival in patients with severe PH (hazard ratios of 0.537 [0.370–0.781], 0.461 [0.233–0.913], and 0.435 [0.215–0.8] for IIP-PH, IPF-PH, and IIP-PH with nintedanib/pirfenidone background therapy), but not in patients with less severe hemodynamic impairment, supported by sensitivity analyses, Heller statistics, and target trial emulation framework analysis. The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combination therapy with PDE5is and inhaled prostacyclin analogues was superior to monotherapy using PDE5is (hazard ratio, 0.341; 0.205–0.566). Conclusions Prognosis in ILD-PH was generally very poor and was related to PH severity. PDE5i treatment in severe IIP-PH and IPF-PH was associated with improved survival, which is to be further verified in controlled trials.
Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor
Groisser, Alissa , Frantz, Amy, Geller, James I. , Ortiz, Michael V. , Walterhouse, David , Ranalli, Mark , Woods‐Swafford, Wendy, Schoettler, Peter , Garrington, Timothy , Mullen, Elizabeth A. , Ash, Shifra , Bardhan, Pooja, Dome, Jeffrey S. , Dome, Jeffrey S , Groisser, Alissa R. , Balis, Frank M.

Mayo Clinic

Pediatric Blood & Cancer | July 26, 2025 | Volume: 72 | Issue: 10 | Pages: No page available

10.1002/pbc.31915 | PMID 40714994 Get It

ABSTRACTBackgroundThe Pediatric Oncology Group P9262 Phase 2 study of single‐agent paclitaxel demonstrated one complete response (CR), one partial response (PR), and four with stable disease (SD) among 15 patients with recurrent Wilms tumor (WT). Based on this activity, paclitaxel‐containing regimens have been used as salvage therapy for treatment‐refractory WT. We conducted a multi‐institutional retrospective study to further characterize the clinical activity of paclitaxel‐containing regimens in recurrent WT.MethodsTwelve institutions submitted anonymized data from patients with relapsed WT treated with paclitaxel. Response after one or two cycles of a paclitaxel‐containing regimen was reported according to Response Evaluation Criteria in Solid Tumors.ResultsTwenty‐eight patients with a median age at diagnosis of 5.5 years (range: 3 months to 31.9 years) were reported. Twenty had non‐anaplastic WT; eight had diffuse anaplasia (DA). Stage at diagnosis was I (n = 1), II (n = 1), III (n = 11), IV (n = 14), and V (n = 1). Patients received a mean of 8.5 anticancer drugs (range: 6–12) before paclitaxel, including eight who received high‐dose therapy/stem cell transplant. Paclitaxel (n = 13) or nab‐paclitaxel (n = 15) were predominantly administered in combination with other agents, most commonly doxorubicin and/or gemcitabine. Eleven of 26 patients with measurable disease had a partial response (7 = non‐anaplastic; 4 = DA), four had stable disease, and 11 had progressive disease. Two patients without measurable disease maintained a complete response for 12 and 16 months. The mean duration without progression was 7.6 months (range: 1–35 months).ConclusionsPaclitaxel‐containing regimens appear to be active against heavily pretreated WT with either non‐anaplastic or DA histology. Prospective studies are warranted to formally evaluate the efficacy of paclitaxel‐based therapies.
Ground-Glass Opacities in Pulmonary Arterial Hypertension—Results from the PVDOMICS Study
Menon, Divya Padmanabhan , Gochanour, Benjamin R. , Beck, Gerald J. , Erzurum, Serpil C. , Farha, Samar , Finet, J. Emanuel , Grünig, Gabriele , Hill, Nicholas S. , Lempel, Jason K. , Mathai, Stephen C. , Renapurkar, Rahul D., Hemnes, Anna , Mathai, Stephen C , Waxman, Aaron B. , DuBrock, Hilary M , Frantz, Robert P. , Rosenzweig, Erika B. , Borlaug, Barry A. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , DuBrock, Hilary M.

Mayo Clinic

Annals of the American Thoracic Society | July 18, 2025 | Volume: 22 | Issue: 12 | Pages: 1863-1873

10.1513/annalsats.202503-333oc | PMID 40680159 Get It

Abstract Rationale Pulmonary hypertension (PH) is associated with significant morbidity and mortality. Ground-glass opacities (GGOs) are common in Group 1 PH, but their clinical significance is unclear. Objectives We sought to characterize the clinical features and outcomes of patients with Group 1 PH with and without GGOs in the PVDOMICS study, a prospective multicenter cohort study aimed at deep phenotyping PH. Methods Patients with incident and prevalent PH were enrolled across seven U.S. centers. We included patients with Group 1 PH and excluded those with parenchymal lung disease or without chest imaging, resulting in a cohort of 242 patients. Results GGOs were common among patients with Group 1 PH (43% prevalence), associated with female sex, younger age, prostanoid use, and longer disease duration. GGOs were more common among patients with familial pulmonary arterial hypertension and pulmonary veno-occlusive disease. GGOs were associated with established markers of disease severity, including echocardiographic (right ventricular systolic pressure and tricuspid annular plane systolic excursion), biomarkers (N-terminal pro B-type natriuretic peptide), and worse hemodynamics (higher mean pulmonary artery pressure, pulmonary vascular resistance, and pulmonary artery wedge pressure). GGOs were associated with worse transplant-free survival (hazard ratio, 2.49; 95% confidence interval = 1.43–4.32; P = 0.001) and had independent prognostic value for predicting transplant-free survival after adjusting for European Society of Cardiology and European Respiratory Society risk stratification (hazard ratio, 2.19; 95% confidence interval = 1.20–3.99; P = 0.01). Conclusions Overall, GGOs were associated with specific clinical characteristics and disease phenotypes, as well as worse hemodynamics, longer disease duration, prostanoid use, and worse survival. Future studies evaluating the pathophysiology and “omic” correlates of GGOs are warranted. Clinical trial registered with www.clinicaltrials.gov (NCT02980887).
Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta‐Registry
Jose, Arun , Yogeswaran, Athiththan , Fünderich, Meike , Kiely, David G. , Sweatt, Andrew J. , Zamanian, Roham T. , Mouawad, Antoine , Balasubramanian, Aparna , Wilkins, Martin R. , Olschewski, Horst , Eichstaedt, Christina A. , Sіrenko, Yu.M. , Majeed, Raphael W. , Wilhelm, Jochen , Tello, Khodr , Elwing, Jean , Seeger, Werner , Thenappan, Thenappan , Ghouleh, Imad Al , Fuenderich, Meike , Kiely, David , Mouawad, Antoine , Wilkins, Martin , Sahay, Sandeep , Giannakoulas, George , Cajigas, Héctor , Frantz, Robert P , Ghio, Stefano , Majeed, Raphael W , Tello, Khodr , Elwing, Jean M , Seeger, Werner , Olschewski, Horst , Thenappan, Thenappan , Jose, Arun , Yogeswaran, Athiththan , Balasubramanian, Aparna , Hassoun, Paul M. , Lawrie, Allan , Howard, Luke , Sahay, Sandeep , Kovács, Gábor , Saleh, Khaled Musa Mohammad , Sabbour, Hani Mohamed , Grünig, Ekkehard , Arvanitaki, Alexandra , Torbas, O.O. , Frantz, Robert P. , Scelsi, Laura , Ghio, Stefano , Ghofrani, Hossein Ardeschir , Grimminger, Friedrich

Mayo Clinic

Pulmonary Circulation | July 9, 2025 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/pul2.70121 | PMID 40636151 Get It

ABSTRACTPortopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear. We performed a retrospective cohort study of PoPH patients from the international pulmonary hypertension (PH) meta‐registry, PVRI GoDeep. PAH was defined by a mean pulmonary arterial pressure > 20 mmHg, pulmonary arterial wedge pressure ≤ 15 mmHg, and a pulmonary vascular resistance (PVR) > 2 Wood Units. PoPH diagnoses were assigned by each center's PH specialist based on international guidelines at the time of enrollment. 246 incident PoPH patients met eligibility criteria and were included in the analysis, equally split between males (51%) and females (49%), with a median age of 54 years. When compared to both patients with IPAH and those with other subtypes of PAH (not classified as PoPH or IPAH), those with PoPH had significantly lower 5‐year survival rates (46% vs. 68% vs. 65%, log‐rank p < 0.001). Amongst the PoPH patients, however, there was no significant difference in 5‐year survival when dichotomized by disease severity, either by a PVR of 5 Wood Units or a CI of 2.5 L/min/m2. Treatment of the PoPH patients with PAH‐targeted therapies was associated with significantly higher 5‐year survival rates compared to those not receiving such treatments, as shown by Kaplan–Meier analysis. This survival benefit was observed for PDE5i (50% vs. 34%, log‐rank p = 0.029), ERA (58% vs. 34%, log‐rank p < 0.001), and the combination of PDE5i and/or ERA (51% vs. 22%, log‐rank p < 0.001), as well as any PAH‐targeting treatment (50% vs. 26%, log‐rank p = 0.007). Corresponding survival advantage was noted when including only PoPH patients with MELD Score ≥ 13. PoPH is a disease with significantly worse long‐term survival than other PAH subtypes, but targeted PAH therapy is associated with a robust survival benefit. Survival did not differ across high‐risk PVR and cardiac index thresholds, suggesting the factors that influence prognosis and survival in PoPH may be unique as compared to other PAH subtypes, and warrant further investigation.
Metabolomic Evidence of Biological Overlap with Heart Failure with Preserved Ejection Fraction in a Subset of Pulmonary Arterial Hypertension
Reddy, Yogesh N.V. , Asokan, Aneesh K , Hemnes, Anna R. , Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, J. Emanuel , Grünig, Gabriele , Jellis, Christine , Mathai, Stephen C. , Simpson, Catherine E. , Hemnes, Anna , Mathai, Stephen C , Simpson, Catherine E , Nishimura, Rick , Frantz, Robert P. , Hassoun, Paul M. , Barnard, John , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Tang, W H Wilson , Nair, K. Sreekumaran , Borlaug, Barry A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 13, 2025 | Volume: 211 | Issue: 9 | Pages: 1701-1713

10.1164/rccm.202501-0034oc | PMID 40504754 Get It

Abstract Rationale A subset of patients with group 1 pulmonary hypertension (PH) have superimposed left heart abnormalities with unclear metabolic implications. Objectives To compare serum/transpulmonary metabolome between group 1 PH stratified by heart failure with preserved ejection fraction (HFpEF) probability. Methods Patients with group 1 PH were stratified into low (&lt;25%) and high (⩾75%) HFpEF-ABA (age, body mass index, and atrial fibrillation) probability, with healthy control subjects and subjects with clinical HFpEF used for comparison of venous and transpulmonary metabolomics. Measurements and Main Results Group 1 PH + high HFpEF probability (n = 131) was associated with a significant increase in 207 metabolites (false discovery rate [FDR] P &lt; 0.05 and fold change &gt;1) (n = 193, t test) and a significant decrease in 231 metabolites (FDR P &lt; 0.05 and fold change &lt;1) (n = 193, t test) compared with group 1 PH + low HFpEF probability (n = 62). Group 1 PH + high HFpEF probability was associated with enhanced tryptophan metabolism with higher downstream kynurenine metabolite concentrations and lower serotonin concentrations (FDR P &lt; 0.002 for all, n = 193, t test). Linoleate (precursor to arachidonic acid and prostaglandins) and arginine and homoarginine (precursors to nitric oxide) were all lower in group 1 PH + high HFpEF probability (FDR P &lt; 0.03 for all, n = 193, t test). Metabolome changes in group 1 PH + high HFpEF probability overlapped with clinical HFpEF (n = 240) but were abnormal relative to control subjects (n = 85) (P &lt; 0.0001 for all, n = 456, t test). There was no evidence of differential transpulmonary uptake/release of most metabolites, suggesting probable nonpulmonary origin (except for serotonin, interaction P = 0.04; and kynurenine, interaction P = 0.03; n = 433, mixed model). Conclusions Patients with group 1 PH + high HFpEF probability have a unique metabolome characterized by enhanced tryptophan-kynurenine pathway breakdown, deficiency of amino acids (such as glycine and serine), lower serotonin, and decreased prostaglandin and nitric oxide precursors. Despite fulfilling clinical criteria for group 1 PH, these metabolome changes were comparable with clinical HFpEF, supporting biological overlap between these two forms of PH.
Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension
Reddy, Yogesh N.V. , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, J. Emanuel , Jellis, Christine , Mathai, Stephen C. , Group, PVDOMICS Study, Hemnes, Anna , Horn, Evelyn M , Jellis, Christine L , Mehra, Reena , Tang, W H Wilson , Borlaug, Barry A , Nishimura, Rick , Rosenzweig, Erika B , Frantz, Robert P , Rischard, Franz P , Leopold, Jane A , Hassoun, Paul M , Mathai, Stephen C , Mehra, Reena , Tang, W.H. Wilson , Borlaug, Barry A. , Group, PVDOMICS Study

Mayo Clinic

Circulation: Heart Failure | May 29, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circheartfailure.125.012912 | PMID 40438933 Get It

BACKGROUND: Patients with lung disease, sleep apnea, and chronic thromboemboli can develop pulmonary hypertension, currently classified as group 3 or 4. Many of these patients also have risk factors for heart failure with preserved ejection fraction (HFpEF), but the optimal approach to identify the disease overlap remains unclear. METHODS: Pretest probability for HFpEF was determined using the HFpEF-ABA (age, body mass index, atrial fibrillation) algorithm among adjudicated group 3 or 4 patients at risk for pulmonary hypertension in the PVDOMICS study (Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics). Patients were stratified by current resting right heart catheterization criteria, and in a separate analysis, stratified only by HFpEF-ABA probability into low (<25%), intermediate, and high (≥75%) HFpEF probability groups. RESULTS: Among 598 patients with group 3 disease, 27% (n=161) had elevated pulmonary capillary wedge pressure (PCWP) with postcapillary pulmonary hypertension even at rest, which was associated with the highest exercise PCWP. However, regardless of this resting PCWP-based classification, a larger subset had intermediate-to-high HFpEF-ABA probabilities (32% [n=197] high and 57% [n=358] intermediate HFpEF probability). High HFpEF probability in group 3 disease was associated with higher resting and dynamic PCWP response to NO, fluid, and exercise ( P <0.0001 for all). These changes were comparable with more traditionally defined HFpEF without pulmonary vascular disease (n=61) but less severe than those with combined precapillary and postcapillary pulmonary hypertension HFpEF (n=31; interaction P =0.006). Increasing HFpEF probability in group 3 disease was associated with worse left heart remodeling, quality of life, 6-minute walk distance, and peak VO 2 ( P <0.0001 for all). Findings were replicated in group 4 disease (n=102). CONCLUSIONS: Quantifying pretest probability for HFpEF in patients with sleep apnea, lung disease, or chronic thromboemboli identifies a progressive gradient for dynamic PCWP abnormalities with worse functional status and quality of life. These subclinical left heart abnormalities are not universally detectable by resting right heart catheterization alone and call for further study of whether strategies to prevent or treat HFpEF might improve functional status in these patients with high risk of occult HFpEF.
Characteristics of Daily Walking Bouts as Valid and Reliable Indicators of Exercise Capacity in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)
Rehman, Rana Zia Ur , Parisi, Federico , Ashraf, Noman , Chatterjee, Meenakshi , Frantz, Robert P. , Hemnes, Anna R. , Manyakov, Nikolay V. , Yardibi, Tarik, Selej, Mona , Mansi, Tommaso , Dunnmon, Preston , Selej, Mona , Kaliukhovich, Dzmitry A , Frantz, Robert P , Hemnes, Anna , Carrasco‐Zevallos, Oscar M.

Mayo Clinic

Pulmonary Circulation | May 27, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/pul2.70097 | PMID 40433632 Get It

ABSTRACTThere is a need for objective, continuous and remote assessment of exercise capacity in patients with pulmonary arterial hypertension (PAH). Using data from the TRACE study, in which 108 adult patients with PAH were continuously monitored with a wrist‐worn accelerometer, we evaluated whether actigraphy can facilitate continuous monitoring of exercise capacity. Distributions of step rate, distance and duration of patient's walking bouts were estimated at baseline, Week 16 and Week 24 using 2‐week periods of actigraphy data. Twenty‐one metrics per walking bout characteristic were described (mean, standard deviation, 19 percentiles [5th–95th]). The relationships between these metrics and the 6‐min walk distance (6MWD), Borg dyspnea index (BDI), and the PAH Symptoms and Impact questionnaire (PAH‐SYMPACT) Physical Impact domain score were assessed at the three timepoints. Test‐retest reliability, and discriminant and known‐group validity of each metric were also evaluated. All metrics of step rate and bout distance were significantly correlated with 6MWD (Pearson's correlation coefficients: 0.34–0.67; p < 0.005) and the PAH‐SYMPACT Physical Impact domain score (Pearson's correlation coefficients: −0.51 to −0.32; p < 0.05) at all timepoints. Negative correlations were also observed with the BDI and the actigraphy‐derived metrics, with the majority reaching significance. Strong test‐retest reliability was demonstrated (intra‐class correlation coefficient ≥ 0.70). The metrics differentiated well between patients with varying disease severity levels. In conclusion, actigraphy‐derived metrics of patients' walking bouts correlate significantly with 6MWD, BDI and physical impacts of PAH, indicating the utility of actigraphy in facilitating continuous monitoring of exercise capacity in adult patients with PAH.Trial RegistrationClinicalTrials.gov: NCT03078907; URL: clinicaltrials.gov.
Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Rosen, Darin , Kolb, Todd M. , Mathai, Stephen C. , Suresh, Karthik , D’Amico, Rachel, Hsu, Steven , Tedford, Ryan J. , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Farha, Samar , Grünig, Gabriele , Jellis, Christine , Kwon, Deborah , Park, Margaret , Xiao, L, Fessel, Jeffrey , Fu, Yongping , Postow, Lisa, Schmetter, Barry, Sutliff, R, Tian, Xuefei , Joseloff, Elizabeth, Wong, Brenda , Lawler, Laurie, Maron, B, Haythe, Jennifer , Krishnan, Udhay , Payne, David A., Bergman, Geoffrey , Bastert, K, Devereux, Richard B. , Kim, Ju Youn , Lohman, Julia, Racanelli, Alexandra C. , Ricketts, Michelle L., Sobol, Irina , Singh, Harsimran , Weinsaft, Jonathan W. , Mathai, S.C. , Carey, Kyle A. , Damico, Rachel L. , Enobun, Blessing , Sanni, Y, Brock, Heinz, Durst, Louise A., Head, Denise , Foley, Thomas A. , Gochanour, Benjamin R. , Halbach, H, Krowka, Michael J. , Menon, David K. , Park, Gyu Tae , Redfield, Margaret M. , Rohwer, Kristi, Williamson, Eric E. , Vanderpool, R, Yuan, Jason X.‐J. , Lim, C.S., Abidov, Aiden , Erickson, Harold , Cunningham, James M. , Pugh, Meredith E., Robbins, Ivan M. , Beck, Gerald J. , Aldred, Micheala A. , Asosingh, Kewal, Aylor, Joan, Beck, B, Borowski, A, Collart, Clara, Comhair, S.A.A., Drinko, Jeanne K., Finet, J. Emanuel , Flinn, Aisling M. , Geraci, M, Jacob, Miriam , Kanta, Alexandra, Larive, Brett , Lempel, Jason K. , Li, Minghui , MacKrell, J., Neumann, D., Nawabit, R, Odabashian, Jill, Olman, Mitchell A. , Park, M, Radeva, Milena , Renapurkar, R, Sharp, Jacqueline, Sherer, Stefan, WHW, Tang, Thomas, Jason , Wadih, K, Wells, Simon P. , Wilcox, Jane, Yu, S, Rounds, Sharon , Bull, Todd , Cadigan, John B., Rosen, Darin T , Rosenzweig, Erika B , Rischard, Franz P , Frantz, Robert P , Beck, Gerald J , Hill, Nicholas S , Barnard, John , Grunig, Gabriele , Jellis, Christine L , Kwon, Deborah H , Mehra, Reena , Park, Margaret M , Tang, W H Wilson , Hassoun, Paul M , Simpson, Catherine E , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Tedford, Ryan J , Mathai, Stephen C , Hsu, Steven , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , Barnard, John , Mehra, Reena , Tang, W.H. Wilson , Hassoun, Paul M. , Simpson, Catherine E. , Xiao, L, Fu, Y‐P, Gray, Michael P. , Wong, B, Waxman, Aaron B. , Systrom, David M , Brady, David J. , Chung, Wendy K. , Payne, D, Karas, Maria , Lohman, J, Ricketts, M, Balasubramanian, A, Carey, K, Gao, Lei , Halushka, Marc K. , Kass, David A. , Lin, Ting‐Tse , Mukherjee, Monica , Roth, J, Sanni, Y, Weiss, Robert E. , Zimmerman, Stefan L , Behfar, Atta , Borlaug, Barry A. , Brock, H Du, Head, D, Kane, Garvan C. , Sands, T. , Scott, Christopher G. , Terzic, André , Williamson, E, Garcia, Joe G. N. , Lim, C, Desai, Akshay S , Hansen, L, Newman, J, Brittain, Evan L , Cheng, Feixiong , Filippo, F Di, Flinn, A, Hu, Bo , Jaber, Wael A. , Kanta, A, Martín, Maite Velázquez , McCarthy, Kevin , Ramos, J, Wiggins, K, Willard, Belinda B. , Benza, Raymond L. , Fang, James C. , Gomberg‐Maitland, Mardi

Mayo Clinic

Journal of the American Heart Association | May 22, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/jaha.124.041127 | PMID 40401597 Get It

Background Right ventricular (RV) maladaptation to elevated pulmonary afterload is the primary determinant of outcomes in pulmonary artery (PA) hypertension; however, the pathobiological mechanisms underlying RV decompensation remain poorly understood. Methods We performed global untargeted metabolomics on plasma from 55 patients who underwent gold‐standard RV‐PA coupling measurements using multibeat pressure volume loop assessment in a single‐center cohort and from 1027 patients with coupling surrogate measurements in a larger multicenter cohort, the PVDOMICS (Pulmonary Vascular Disease Phenomics) study. Age and sex‐adjusted linear regression was performed to identify associations between metabolites and coupling metrics. Additionally, we performed a metabolic flux analysis using gene expression data from RV tissue in an independent cohort of 32 patients. Partial least squares–discriminant analysis was used to identify metabolites and reactions characteristic of the decompensated RV. Results RV‐PA coupling was negatively associated with tricarboxylic acid (TCA) cycle intermediate levels. Specifically, plasma α‐ketoglutarate and fumarate were significantly associated with all coupling metrics in both cohorts. Metabolic flux analysis indicated that decompensated RVs exhibited aberrant TCA cycle activity, including reduced acetyl coenzyme A entry and increased lactate elimination, suggesting a shift from the TCA cycle toward glycolysis at the RV tissue level. Conclusions We identify an association between circulating TCA cycle intermediate levels and RV‐PA uncoupling in 2 independent cohorts, and dysregulated TCA cycle metabolism in decompensated PA hypertension RVs, suggesting that aberrant TCA cycle metabolism could represent a hallmark of RV maladaptation in PA hypertension. Further study of this pathway is warranted to develop novel biomarkers of RV function or RV‐targeted therapies.
Repeatability of Magnetic Resonance Elastography‐Derived Mechanical Parameters in Intracranial Meningiomas
Aunan‐Diop, Jan Saip , Friismose, Ancuta Ioana , Halle, Bo , Pedersen, Christian Bonde , Mussmann, Bo Redder , Hojo, Emi , Yin, Ziying , Nortvig, Mathias Just , Lagerstrand, Kerstin , Poulsen, Frantz Rom , Mussmann, Bo , Yin, Ziying , Friismose, Ancuta I , Hojo, Emi , Poulsen, Frantz Rom , Halle, Bo

Mayo Clinic

Journal of Magnetic Resonance Imaging | May 15, 2025 | Volume: 62 | Issue: 4 | Pages: 1047-1058

10.1002/jmri.29825 | PMID 40372143 Get It

ABSTRACTBackgroundMagnetic resonance elastography (MRE) quantifies tissue viscoelasticity, offering insights into intracranial meningiomas. MRE‐derived parameters, including the storage modulus (G') and the magnitude of the complex modulus (|G*|), may aid neurosurgical planning, but their repeatability remains unexplored in brain tumors.Purpose/HypothesisTo evaluate the repeatability of G' and |G*| in meningiomas, the influence of tumor volume and spatial location on variability, and ranking stability across paired elastograms.Study TypeProspective.Population/SubjectsSeventeen paired MRE scans from 16 patients with meningiomas (mean age 64 ± 12 years, 10 females) scheduled for resection.Field Strength/SequenceMRE was performed on a 3 T system using a single‐shot spin‐echo echo‐planar imaging (SE‐EPI) sequence.AssessmentTumors were segmented on contrast‐enhanced T1‐weighted images; distance and volume metrics were extracted. Regions of interest were applied to G' and |G*| elastograms. Repeatability was evaluated using the coefficient of variation (CV%). Ranking stability was assessed by comparing median G' or |G*| values.Statistical TestsThe difference in CV% was assessed using the Wilcoxon signed rank test. Linear regression assessed the effect of tumor volume and distance from the external occipital protuberance (EOP) on CV%. The Wilcoxon signed‐rank test evaluated ranking stability and scan‐rescan CV%. Statistical significance was defined as p < 0.05.ResultsThe difference in CV% G' (14.89 ± 12.32) and CV% |G*| (13.88 ± 12.60) was not significant (p = 0.61). Tumor volume inversely correlated with CV% (G': β = −0.75 |G*|: β = −0.59). Tumor‐EOP distance had no significant effect (G': p = 0.58, |G*|: p = 0.23). Rankings remained stable (G': p = 0.82, |G*|: p = 0.71).Data ConclusionMRE‐derived parameters are repeatable in intracranial meningiomas, with G' and |G*| being equally stable. Larger tumors yielded more consistent estimates. Preserved ranking stability supports the use of MRE in preoperative planning.Evidence Level2.Technical EfficacyStage 2.
Addition of Patient-Reported Outcomes Improves Discrimination of Survival Prediction Models in Pulmonary Arterial Hypertension
Balasubramanian, A. , Simpson, C., Hassoun, P.M., Larive, Brett , Rosenzweig, E.B., Hill, Nicholas S. , Erzurum, S.C., Mathai, S.C., Group, PVDOMICS Study, Mathai, Stephen C. , Balasubramanian, Aparna , Mathai, Stephen C , Balasubramanian, Aparna , DuBrock, Hilary M. , Lammi, Matthew R. , Kolb, Todd M. , Hassoun, P.M., Horn, Evelyn M. , Hemnes, Anna R. , Leopold, Jane A. , Rischard, Franz , Frantz, Robert P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7611-A7611

10.1164/ajrccm.2025.211.abstracts.a7611 Get It

Abstract Rationale: The 7th World Symposium on Pulmonary Hypertension highlighted the importance of patient-reported outcomes in clinical assessment of pulmonary arterial hypertension (PAH). Patient-reported outcomes, such as health-related quality of life (HRQOL), have been associated with morbidity and mortality in PAH, but the added value of HRQOL measures to validated risk prediction models remains unknown. Methods: Adults with RHC-proven PAH from the Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) Study, a multi-center observational study, were included in this study. The Pulmonary Hypertension Association Registry (PHAR) was used as a validation cohort. HRQOL was measured using the emPHasis-10 score, where higher scores reflect worse HRQOL. Noninvasive risk assessment was measured by REVEAL Lite 2 risk score, categorized into 3-strata. Cox proportional hazard models were used to model survival evaluating the interaction between risk strata and HRQOL scores, adjusting for age, sex, and incident diagnosis. Harrell's C-statistics were calculated to compare discriminative performance. Results: From the PVDOMICS and PHAR cohorts, 265 and 2671 individuals with PAH and complete emPHasis-10 and REVEAL Lite 2 scores were included. Both cohorts had similar demographics, with an average age of 52±13 and 56±16 years, 75% and 72% female, 81% and 75% White, in the PVDOMICS and PHAR cohorts respectively. Over 87% of PVDOMICS were prevalent cases of PAH, while in the PHAR half were incident. Most individuals (62%) in PVDOMICS were REVEAL Lite 2 low risk, with 16% intermediate and 22% high risk; by contrast, in PHAR 33% were low, 29% intermediate, and 38% high risk. REVEAL Lite 2 scores demonstrated weak to moderate correlation with emPHasis-10 scores in both cohorts (PVDOMICS r=0.48 p&lt;0.001; PHAR r=0.33 p&lt;0.001). Notably, the full range of emPHasis-10 scores were observed in the low-risk individuals across both cohorts. In the PVDOMICS adjusted Cox models, higher emPHasis-10 scores predicted poorer survival (p=0.047) particularly among low-risk individuals (interaction versus high-risk group p=0.08). Similar adjusted models in PHAR demonstrated emPHasis-10 to be a confounder (p=0.001) without significant interaction by risk strata (low vs high-risk interaction p=0.94), but the greatest change in median survival time was observed in the low-risk group (Figure 1). Addition of emPHasis-10 to REVEAL Lite 2 scores improved discrimination in predicting survival (PVDOMICS: C-statistic 0.71 vs 0.73; PHAR: C-statistic 0.67 vs 0.69). Conclusions: Across two multicenter cohorts of incident and prevalent PAH, HRQOL as measured by the emPHasis-10 score improved discrimination for survival, particularly among individuals with lower risk scores.